- Current report filing (8-K)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 6, 2010

HELIX BIOMEDIX, INC.

(Exact name of registrant as specified in its charter)

DELAWARE

033-20897-D

91-2099117

(State or other jurisdiction of

incorporation or organization)

(Commission File Number)

(IRS Employer

Identification No.)

22118 20 ^th Avenue S.E., Suite 204

Bothell, Washington 98021

(425) 402-8400

(Address and telephone number of registrant’s principal executive offices)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.01

Entry into a Material Definitive Agreement.

Item 2.03

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

Item 3.02

Unregistered Sales of Equity Securities.

On May 10, 2010, Helix BioMedix, Inc. (the “Company”) consummated the second closing of its note and warrant offering and issued to two accredited investors convertible promissory notes in the aggregate principal amount of $300,000 (the “Notes”) and five-year warrants to purchase an aggregate of 75,000 shares of the Company’s Common Stock at an exercise price per share equal to $0.80 (the “Warrants”). A description of the terms and conditions of the Notes and Warrants is contained in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 8, 2010. This issuance was exempt from registration pursuant to Rule 506 of Regulation D under Section 4(2) of the Securities Act of 1933, as amended.

Item 1.01

Entry into a Material Definitive Agreement.

On May 6, 2010, the Company entered into a Second Amendment to First Amended and Restated License Agreement (the “Second Amendment”) with Grant Industries, Inc. (“Grant Industries”), which amends the First Amended and Restated License Agreement between the parties dated September 12, 2007 as amended effective as of December 10, 2008 (the “Agreement”). The Second Amendment imposes a different royalty obligation on Grant Industries with respect to sales to a specific customer of certain of the Company’s proprietary peptide premix.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.